THE PROSPECTS FOR INHALATION THERAPY OF RHINOSINUSITIS

Glucocorticoids today are widely used for the treatment of rhinosinusitis. Intranasal Glucocorticoids therapy is actively used in the form of sprays. However, inhalation treatment of rhinosinusitis is rare, which is strange when intensive use of aerosol therapy for pulmonary diseases. The aim of this work is to estimae the probability of systemic adverse corticosteroids effects by inhalation use with Pari Sinus device (сompressor PARISINUS with PARI LC SINUS nebuliser). The study was conducted on 30 healthy volunteers who received daily for a week inhalation of dexamethasone solution using the Pari Sinus. This hormone was chosen because it has a strong glucocorticoid in the absence of mineralocorticoid activity. Cortisol and glucose in venous blood were determined after a course of inhalation. The use of inhaled dexamethasone statistically significantly (р˂0,05) did not affect the levels of cortisol and glucose, which may indicate the absence of significant systemic adverse effects through the hypothalamic-pituitary-adrenal axis suppression. The average values of cortisol and glucose, respectively, was 343±93,4 nmol/l and of 4,51±0,49 mmol/l. Both values are placed in the population average (23-626 nmol/l for cortisol and ≤6,1 for glucose). There fore, we can conclude about the safety of intranasal nebulizer therapy, which makes it a promising treatment for rhinosinusit is because the drug directly penetrates into the paranasal sinuses. In our opinion, a wider use of topical inhalation therapy for rhinosinusitis is needed, which in some cases may lead to the abandonment of systemic drug therapy